A tumor active targeting β-cyclodextrin based nanocarrier β-NC-OEI-SS-FA was designed by the modification of star shaped cationic derivatives β-NC-OEI with folic acid through a disulfide bond, to co-deliver chemotherapeutic paclitaxel and the Nur77 gene for overcoming Bcl-2 mediated non-pump resistance by an "enemy to friend" strategy for potential drug resistant cancer therapy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: